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Background and Objectives: Integrating acute HIV-infection
(AHI) testing into clinical settings is critical to prevent transmission,
and realize potential treatment-as-prevention benefits. We evaluated
acceptability of AHI testing and compared AHI prevalence at
sexually transmitted infection (STI) clinics and HIV testing and
counseling (HTC) clinics in Lilongwe, Malawi.
Methods: We conducted HIV RNA testing for HIV-seronegative
patients visiting STI and HTC clinics. AHI was defined as positive
RNA and negative/discordant rapid antibody tests. We evaluated
demographic, behavioral, and transmission-risk differences between
STI and HTC patients and assessed performance of a risk-score for
targeted screening.
Results: Nearly two-thirds (62.8%, 9280/14,755) of eligible
patients consented to AHI testing. We identified 59 persons with
AHI (prevalence = 0.64%)–a 0.9% case-identification increase.
Prevalence was higher at STI [1.03% (44/4255)] than at HTC
clinics [0.3% (15/5025), P , 0.01], accounting for 2.3% of new
diagnoses vs 0.3% at HTC clinic. Median viral load (VL) was
758,050 copies per milliliter; 25% (15/59) had VL $10,000,000
copies per milliliter. Median VL was higher at STI (1,000,000
copies/mL) compared with HTC (153,125 copies/mL, P = 0.2).
Among persons with AHI, those tested at STI clinics were more
likely to report genital sores compared with those tested at HTC
clinics (54.6% vs 6.7%, P , 0.01). The risk score algorithm
performed well in identifying persons with AHI at HTC clinics
(sensitivity = 73%, specificity = 89%).
Conclusions: The majority of patients consented to AHI testing.
AHI prevalence was substantially higher in STI clinics than HTC
clinics. Remarkably high VLs and concomitant genital scores demon-
strate the potential for transmission. Universal AHI screening at STI
clinics, and targeted screening at HTC centers, should be considered.
Key Words: acute HIV infection, AHI screening, Malawi, HIV
testing and counseling
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INTRODUCTION
Acute HIV-infection (AHI) is a 10–12 week period
immediately after HIV acquisition, when HIV RNA is detect-
able but anti-HIV antibodies are not. Characterized by
unrestricted replication of HIV and extremely high viral loads,
persons with AHI are highly infectious1–5 and may be
responsible for a substantial proportion of sexual and mother-
to-child HIV transmission.6–9 Failure to identify persons with
AHI may compromise HIV prevention efforts, dampening the
potential population-wide benefits of treatment-as-prevention–
the use of early and universal antiretroviral therapy.10 This is
especially important in Malawi which embraced a treatment-
as-prevention approach in its prevention of mother-to-child
transmission program in 2011 and is advancing this strategy
through its 90-90-90 targets in its 2015–2020 National
Strategic Plan.
Integrating feasible and acceptable AHI testing strategies
into clinical settings in sub-Saharan Africa may be critical to
prevent onward transmission and realize the potential patient
and population benefits of treatment-as-prevention. In sub-
Saharan Africa, nearly 40% of ongoing HIV transmission may
be attributed to persons in the first 5 months of infection–many
of whom would be missed using traditional antibody testing
approaches.11 Without AHI testing, persons with AHI are told
they are HIV-negative. Believing they are HIV-uninfected,
they are more likely to continue engaging in high-risk sexual
behaviors during the highly-infectious acute phase of infection,
and may remain undiagnosed for extended periods.12–14
Despite the brevity of the period, the proportion of
persons with AHI at the time of HIV testing is nontrivial, and
screening for acute infection may be cost-effective.15–18 In
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sub-Saharan Africa, 1%–3% of patients in outpatient clinics
who met setting-specific clinical criteria had AHI.19–22 This
prevalence varies with clinic setting. For example, among men
visiting a dermatology clinic in Lilongwe, Malawi, 0.2% of
HIV-seronegative patients were acutely infected,23 compared
with 2%–5% of HIV-seronegative patients at a nearby sexually
transmitted infection (STI) clinic.23,24 The risk profiles of
persons in these clinical settings determine AHI rates. Some
patients seeking testing at HIV testing and counseling (HTC)
clinics are at high risk for HIV infection, but may have
different risk behaviors and biologic cofactors than their STI
clinic counterparts, and the prevalence of AHI in this
population is unknown. AHI prevalence and risk factors have
never been compared in these 2 settings, to our knowledge.
In this article, we describe the AHI testing component
of a pilot randomized controlled trial assessing behavioral and
antiretroviral interventions during acute HIV infection.25 In
this analysis, our objective was to evaluate patient accept-
ability of testing for AHI, and examine AHI prevalence,
population characteristics, and risk profiles among patients
seeking HIV testing at STI and HTC clinics in Lilongwe,
Malawi. We also assessed performance of an existing risk
score in predicting AHI among screened populations at each
clinic.26 Outcomes are designed to inform AHI screening
strategies and priorities in sub-Saharan Africa.
METHODS
Study Design and Setting
We conducted a cross-sectional analysis to describe
testing for AHI among HIV-seronegative patients in the
context of a larger pilot study (ClinicalTrials.gov
#NCT01450189). We conducted AHI testing at 2 HTC and
2 STI clinics in Lilongwe, Malawi. Lilongwe, the capital city
of Malawi, has a population of approximately 1 million
persons and an estimated adult HIV prevalence of 17%.27 The
4 selected sites (Lighthouse HTC, Martin Preuss Centre HTC,
Bwaila District Hospital STI, and Kamuzu Central Hospital
STI clinics) are among the primary access points for HIV
testing in Lilongwe. In total, the 2 HTC sites historically have
served approximately 14,000 patients per year; the 2 STI
clinics serve nearly 10,000 patients per year. Differences
between these 2 clinic types include provision of syndromic
management of STI symptoms (available at STI, not at HTC
clinics) and colocation of ART services (available at HTC,
not at STI clinics). Additionally, persons testing at HTC
clinics are more likely to have been referred specifically for
HIV testing from either inpatient units or a sexual partner,
whereas this is less often the case at STI clinics where patients
may be referred specifically for STI testing, but not neces-
sarily HTC. Although not universally true, the HIV preva-
lence at HTC clinics in this evaluation are historically higher
than prevalence rates observed at STI clinics in this study.
Study Population and Eligibility
As per Malawi national guidelines, opt-out HIV
testing and counseling is conducted using a serial testing
algorithm with Alere Determine HIV-1/2 (Alere, Inc,
Waltham, MA) and Uni-Gold Recombigen HIV-1/2
(Trinity Biotech, Bray, Ireland) rapid antibody tests. A
tie-breaker is used in the event of discordant results.
Patients were eligible for AHI testing if they met the all
the following criteria: (1) had negative or discordant rapid
antibody test results, (2) were $18 year old, (3) lived within
the Lilongwe City catchment area, (4) were willing to provide
locator information for follow-up tracing, and (5) were able to
provide informed consent. Patients who had serious illness
requiring inpatient management or were incarcerated were not
eligible. Patient eligibility and consent were collected by
HTC counselors after completion of routine HIV-antibody
testing procedures and counseling. HIV prevalence was
obtained from routine log data.
Acceptability of screening was assessed by the
proportion of persons agreeing to AHI testing among
those offered.
Study Procedures
We collected basic demographics, locater information,
and AHI- and STI-symptom history (including presence of
fever, diarrhea, or genital ulcers/sores) from all enrolled
participants. Participants had ;500 mL of blood collected in
microtubes by fingerstick. Specimens were stored in ice and
transported daily to a central laboratory. Specimens were
tested within 21 days of initial antibody testing; 98.8% were
tested within 7 days. All specimen and data collection was
conducted by trained HTC counselors employed at the HTC
and STI clinics.
Laboratory Testing
Specimens underwent HIV RNA polymerase chain
reaction (PCR) testing using the COBAS AMPLICOR
HIV-1 MONITOR Test (Roche, Pleasanton, CA) (reportable
range of 50–750,000 copies/mL) or Abbott RealTime HIV-1
m2000 Assay (Abbott Laboratories, Chicago, IL) (reportable
range of 40–10,000,000 copies/mL). Microtubes containing
whole blood were processed and plasma specimens were
pooled in a 9:1 pooling algorithm. Positive pools were
deconstructed and individual specimens tested to identify
which contained detectable HIV RNA.28–31
Definition of Acute HIV Infection
Several definitions of AHI have been described; we
selected that which was easiest to implement in a screening
setting, focusing on markers of early infection that did not
require extensive laboratory investigations.7 Specifically, AHI
was defined as a positive HIV RNA test and negative or
discordant (2 negative, 1 positive) rapid HIV antibody tests.
When sufficient specimen was available, repeat antibody tests
were conducted on samples with detectable HIV RNA to rule
out initially false negative antibody results. Persons with
positive HIV RNA were recontacted based on locator
information provided at the time of testing, and counseled
on their result.
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Statistical Analyses
All analyses were performed using Stata (Version 13.0;
StataCorp, College Station, TX). We evaluated differences
between HTC and STI patients by AHI status and testing site
using t tests, Pearson x2 tests, and Fisher exact test with a =
0.05. We used nonparametric Wilcoxon rank-sum tests to
compare median viral loads (VLs).
Evaluation of Existing Risk Score
We also evaluated performance of an existing risk score
algorithm developed to target AHI testing toward persons at
highest risk.26 With this algorithm, each patient is assigned
points for each of the following predictors: fever (1 point),
body ache (1 point), having more than 1 sexual partner in the
previous 2 months (1 point), diarrhea (2 points), genital ulcer
disease (2 points), and discordant HIV rapid tests (4 points).
Points are summed across predictors to calculate a risk score
for each patient. Previous evaluations targeting AHI screening
to those with a risk score $2 suggest that 40.9% of all STI
patients would meet this AHI testing threshold, and that
95.2% of persons with AHI would be detected. We applied
this score threshold to the entire tested study population, and
evaluated the algorithm performance by clinic type.
Ethical Approval
The National Health Sciences Research Committee of
Malawi, the Biomedical Institutional Review Board at
University of North Carolina, Chapel Hill, and the National
Institute of Allergy and Infectious Diseases Prevention
Science Review Committee approved this study.
RESULTS
Study Population and Acceptability
Between June, 2012 and January, 2014, 35,913 patients
received HTC at enrolling clinics (STI, N = 13,379; HTC, N =
22,525) (Fig. 1). HIV prevalence based on rapid antibody
testing at enrolling clinics was 18.5% (6647/35,913) (STI
14.0%, HTC 21.2%). Among the 29,257 HIV-antibody–
negative or discordant patients, approximately half (53.5%,
15,655) were screened for study eligibility. The remaining
46.5% were not screened for eligibility and no additional
demographic information is available. Overall 6% (900/15,655)
were ineligible, due to age ,18 (1.5%, 235/15,655), living
outside of Lilongwe (2.2%, 337/15,655), serious illness (2.1%,
321/15,121), drug/alcohol use (0.1%, 14/15,086), and/or
imprisonment (0.2%, 26/15,083).
Patient acceptability of AHI testing was moderate; nearly
two-thirds (62.8%, 9280/14,755) of patients identified as
eligible for testing consented to testing. Among consenting
participants, 98.8% (9171/9280) had results available; specimen
clotting or having insufficient specimen volume for HIV RNA
testing were the primary reasons for results not being confirmed.
Approximately half (52.2%) of the 9280 of all persons
tested for AHI were male (Table 1). Average age among all
tested participants was 28.7 years [standard deviation (SD)
8.3 years]. Overall, tested participants reported an average of
1.2 sexual partners in the last 3 months, and 12% (1073/9280)
of tested participants reported having.1 sexual partner in the
last 3 months. Only 11% (1030/9280) of participants reported
condom use at last sex.
Acutely Infected Persons vs Confirmed
HIV-Negative
We identified 59 persons with AHI, a prevalence of
0.64% (59/9171) among persons testing seronegative. The
prevalence of AHI was similar by gender [0.7% (34/4851)
male vs 0.6% (25/4429) female, P = 0.4; Table 2]. Seven
additional persons had detectable HIV RNA but were consid-
ered false negative rapid antibody tests based upon repeat
antibody testing of surplus specimen. Discordant rapid antibody
tests were rare in the study population (0.45%, 70/15,655), but
persons with AHI were more likely to have discordant antibody
test results compared with persons without AHI (23.7% vs
0.4%, P , 0.05; Table 2). We successfully traced 58/59
(98.3%) persons with AHI within 21 days of testing using the
locator/contact forms completed at the time of testing.
Median VL for persons with AHI was 758,050 copies
per milliliter [interquartile range (IQR): 34,984–10,000,000];
the average VL was 3,304,732 copies per milliliter (SD
4,223,083). Median VL was lower among those with discor-
dant rapid antibody tests (276,980 copies/mL, IQR: 13,780–
750,000) compared to persons with concordant negative results
(1,838,060, IQR: 60,820–10,000,000, P = 0.03). Mean VL was
also lower among persons with discordant results (423,292 vs
4,201,179, P = 0.001). Extremely high viral loads were
common: 47% (28/59) had a VL $1,000,000 copies per
milliliter and 25% (15/59) had a VL $10,000,000 copies per
milliliter (upper limit of detection).
Persons with AHI were similar to those without AHI in
terms of average age (28.2 vs 28.8 years, P = 0.3) and
proportion male (57.6% vs 52.2%, P = 0.4). Persons with AHI
had higher mean numbers of sexual partners in the last 3
months than persons without AHI (1.6 vs 1.1, P = 0.1), and
were more likely to have had .1 partner in the last 3 months
(23.7% vs 11.5%, P , 0.01). Genital sores/ulcers were more
common among persons with AHI (42.4% vs 20.6%, P ,
0.01). Persons with AHI were more likely to report having
used a condom at last sex (20.7% vs 11.9%, P = 0.04).
Symptoms frequently associated with AHI were more common
among persons with AHI than those without AHI, including
fever (23.7% vs 8.7%, P , 0.01), diarrhea (10.2% vs 4.3%,
P = 0.03), and body aches (28.8% vs 12.5%, P , 0.01).
STI vs HTC–AHI Prevalence, Risk Behaviors,
and Clinical Symptoms
STI clinic patients were more likely than HTC patients
to be eligible for AHI testing [96.9% (6456/6664) vs 92.3%
(8299/8991), P, 0.01]. In terms of AHI testing acceptability,
screened and eligible participants at STI clinics were more
likely to accept AHI testing compared with eligible partic-
ipants at HTC clinics [65.9% (4255/6456) vs 60.6% (5025/
8299), P , 0.01].
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Among 59 persons with AHI, 44 (75%) were tested at
an STI clinic although only 46% of all persons tested were
from an STI clinic. The AHI prevalence at STI clinics was
1.0% (44/4255), substantially higher than the AHI prevalence
at HTC clinics (0.3%, 15/5025, P , 0.01 Table 1). Gender
breakdown among persons with AHI was similar across sites
[59% (26/44) male (STI) vs 53% (8/15) male (HTC)].
Persons with AHI accounted for 2.3% (44/1913) of all HIV
infections identified in STI clinics vs 0.31% (15/4793) of
HIV-infected persons at HTC clinics, although these figures
underestimate the true proportion of HIV attributable to AHI
in the clinics because many HIV-seronegative patients were
not screened for AHI.
VLs were higher among persons diagnosed in STI
compared with HTC clinics (median VL 1,000,000 copies/mL,
STI vs 153,125 copies/mL, HTC, P = 0.2; mean VL 3,522,480
copies/mL STI vs 2,666,005 copies/mL, HTC, P = 0.5) (Fig. 2).
Over half of persons with AHI from STI clinics had a VL
$1,000,000 copies per milliliter (52.3%) compared with one-
third of persons with AHI at HTC clinics (P = 0.2). Over one-
quarter (27.3%) of persons with AHI from STI clinics had a VL
$10,000,000 copies per milliliter, compared to one-fifth of
those with AHI at HTC clinics (P = 0.6). One-fifth (20.5%) of
persons with AHI from STI clinics had discordant rapid
antibody test results at screening, compared with one-third of
persons with AHI from HTC clinics (P = 0.3).
Patients tested at STI and HTC clinics had similar mean
number of sexual partners in the last 3 months (1.1 vs 1.2,
P = 0.8) (Table 3). Persons with AHI tested at STI clinics had
fewer sexual partners, on average, compared with persons
FIGURE 1. STI and HTC clinic patron eligibility
and testing for AHI. All persons receiving HTC
between June, 2012 and January, 2014 were re-
corded in HTC ledgers. Persons who were anti-
body negative or discordant (1 HIV-positive and 2
HIV-negative rapid antibody tests) were eligible to
be screened for AHI testing. Approximately half
were screened for study eligibility and, among
those screened, approximately 94% were eligible
for AHI testing. Among eligible persons, nearly
two-thirds consented to AHI testing and HIV RNA
results were available for nearly 99%. Of persons
with RNA results available, 66 had detectable RNA;
7 were false negative antibody based on repeat
antibody screening and 59 had AHI. Ab, antibody.
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with AHI tested at HTC clinics (1.4 partners STI vs 2.4
partners HTC, P = 0.05). Despite similar proportions
reporting .1 partner in the last 3 months between clinic
types in the entire screened study population (11.3% STI vs
11.8% HTC, P = 0.4), 18.2% of persons with AHI at STI
clinics reported .1 partner in the last 3 months, compared
with 40% of persons with AHI at HTC clinics (P = 0.09).
Men with AHI at STI clinics reported a mean of 1.7
partners, and over 30% reported having multiple partners in
the last 3 months, whereas no women with AHI at STI
clinics reported having more than 1 sexual partner in the last
3 months.
STI clinic patients were somewhat more likely to report
symptoms than HTC clinic patients (fever 18.2% vs 40.0%,
P = 0.09; diarrhea 6.8% vs 20.0%, P = 0.2; body aches 25.0%
vs 40.0%, P = 0.3). Not surprisingly, genital sores/ulcers were
more common among persons tested at STI clinics compared
with persons tested at HTC clinics (40.2% vs 4.2%, P ,
0.01). Among persons with AHI, those tested at STI clinics
were more likely to report genital sores compared with those
tested at HTC clinics (54.6% vs 6.7%, P , 0.01).
AHI Testing Risk Score Performance
Overall, the risk score algorithm had sensitivity of 71%
and specificity of 73% for identifying persons with AHI. Use
of this risk score in our population would have resulted in
testing only 27.6% (2559/9280) of all persons, and would
have identified 71.2% (42/59) of persons with AHI.
In the STI clinics, algorithm sensitivity was unchanged
(71%), specificity was 54%, and 46.4% (1972/4255) of
participants met the testing threshold. Thus in STI clinics,
by conducting AHI testing on approximately half of all
patients (46%), we would have identified 70.4% (31/44) of all
persons with AHI. In the HTC clinics, sensitivity was 73%
and specificity improved substantially to 89% with only
11.7% of HTC participants meeting the threshold score.
However, testing ;12% of all HTC patients would have
identified 73% (11/15) of all persons with AHI.
DISCUSSION
AHI testing was largely acceptable when implemented
at STI and HTC clinics in Lilongwe. In these high-volume
settings, more than half of seronegative patients were
screened for study eligibility and nearly two-thirds of eligible
TABLE 1. Demographics, Risk Behavior, and Acute HIV at STI
and HTC Clinics, All Screened (N = 9280)
STI (n = 4255),
n (%)
HTC (n = 5025),
n (%)
Age*
18–24 1622 (38.1) 179 (34.2)
25–34 1906 (44.8) 2186 (43.5)
35–44 562 (13.2) 783 (15.6)
$45 165 (3.9) 337 (6.7)
Sex*
Male 2001 (47.0) 2850 (56.7)
Female 2254 (53.0) 2175 (43.3)
No. partners (last 3 mo)
0 217 (5.1) 599 (11.9)
1 3559 (83.6) 3832 (76.3)
2 329 (7.7) 424 (8.4)
3 96 (2.3) 98 (2.0)
$4 54 (1.3) 72 (1.4)
Partners (last 3 mo)
#1 partner 3776 (88.7) 4431 (88.2)
.1 partner 479 (11.3) 594 (11.8)
Condom use*
Yes 362 (8.8) 668 (14.8)
No 3738 (91.2) 3839 (88.2)
Symptoms of genital ulcer
disease*
Yes 1710 (40.2) 209 (4.2)
No 2545 (59.8) 4816 (95.8)
Discordant antibody results
Yes 26 (0.4) 44 (0.5)
No 6638 (99.6) 8947 (99.5)
Acutely infected*
Yes 44 (1.0) 15 (0.30)
No 4211 (99.0) 5010 (99.7)
*Difference between screening sites P , 0.05.
TABLE 2. Demographics, Risk Behavior, and Testing
Outcomes Comparing Persons With AHI to Persons Without
AHI, All Screened (N = 9280)
AHI (n = 59),
n (%)
No AHI (n = 9221),
n (%)
Age
18–24 24 (40.7) 3317 (36.0)
25–34 25 (42.4) 4067 (44.1)
35–44 7 (11.9) 1338 (14.5)
$45 3 (5.1) 499 (5.4)
Sex
Male 34 (57.6) 4817 (52.2)
Female 25 (42.4) 4404 (47.8)
No. partners (last 3 mo)
0 1 (1.7) 815 (8.8)
1 44 (74.6) 7347 (79.7)
2 7 (11.9) 746 (8.1)
3 1 (1.7) 193 (2.1)
$4 6 (10.2) 120 (1.3)
Partners (last 3 mo)*
#1 partner 45 (76.3) 8162 (88.5)
.1 partner 14 (23.7) 1059 (11.5)
Condom use*
Yes 12 (20.7) 1018 (11.9)
No 46 (79.3) 7531 (88.1)
Symptoms of genital ulcer
disease*
Yes 25 (42.4) 1894 (20.5)
No 34 (57.6) 7327 (79.5)
Discordant antibody results*
Yes 14 (23.7) 41 (0.4)
No 45 (76.3) 9180 (99.6)
*Difference between groups P , 0.05.
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patients consented to AHI testing. Almost all persons with
AHI were successfully traced and informed of their HIV
status. The potential for transmission in this group of acutely
infected persons was remarkable; patients had extremely high
VLs, a substantial proportion presented with concomitant
genital ulcer disease, and the majority reported recent
unprotected sexual encounters.
This study represents one of the largest prospective
screening initiatives for AHI among persons presenting to STI
and HTC clinics in sub-Saharan Africa. Although AHI
prevalence has been evaluated in STI clinics,23,24,26,32 to our
knowledge, routine screening has not been incorporated into
an HTC setting previously. We observed important differ-
ences between these 2 populations in terms of AHI preva-
lence and potential infectiousness–both of which were higher
among STI clinic patients. The clinic differences may provide
some insight into transmission dynamics. The increased
proportion of discordant test results and the slightly lower
VL among persons with AHI at HTC suggests that these
persons are detected at a slightly longer interval after
FIGURE 2. Viral loads among persons with
AHI. Median and mean VL for all persons
with AHI was 758,050 copies per milliliter
(IQR: 34,984–10,000,000) and 3,304,732
copies per milliliter (SD 4,223,083),
respectively. VLs tended to be higher
among persons diagnosed in STI clinics,
compared with HTC clinics (median VL
1,000,000 copies/mL vs 153,125 copies/
mL, P = 0.2; mean VL 3,522,480 copies/mL
vs 2,666,005 copies/mL, P = 0.5).
TABLE 3. Demographics, Risk Behaviors, and Testing Outcomes by Clinic Type and Sex, All AHI (N = 59)
STI HTC
Overall (n = 44),
n (%)
Male (n = 26),
n (%)
Female (n = 18),
n (%)
Overall (n = 15),
n (%)
Male (n = 8),
n (%)
Female (n = 7),
n (%)
Mean age, yrs
18–24 18 (40.9) 8 (30.8) 10 (55.6) 6 (40.0) 3 (37.5) 3 (42.1)
25–34 19 (43.2) 14 (53.9) 5 (27.8) 6 (40.0) 4 (50.0) 2 (28.6)
35–44 5 (11.4) 2 (7.7) 3 (15.7) 2 (13.3) 1 (12.5) 1 (14.3)
$45 2 (4.6) 2 (7.7) 0 1 (6.7) 0 1 (14.3)
No. partners (last 3 mo)
0 0 0 0 1 (6.7) 0 1 (14.3)
1 36 (81.8) 18 (69.2) 18 (100) 8 (53.3) 4 (50.0) 5 (57.1)
2 5 (11.4) 5 (19.2) 0 2 (13.3) 2 (25.0) 0
3 3 (6.8) 3 (11.5) 0 1 (6.7) 1 (12.5) 0
$4 0 0 0 3 (20.0) 1 (12.5) 2 (28.6)
Partners (last 3 mo)*
#1 partner 36 (81.8) 18 (69.2) 18 (100) 9 (60.0) 4 (50.0) 5 (71.4)
.1 partner 8 (18.2) 8 (30.8) 0 6 (40.0) 4 (50.0) 2 (28.6)
Condom use
Yes 7 (15.9) 4 (15.4) 3 (16.7) 5 (35.7) 3 (37.5) 2 (33.3)
No 37 (84.1) 22 (84.6) 15 (83.3) 9 (64.3) 5 (62.5) 4 (66.7)
Discordant antibody
results
Yes 9 (20.4) 4 (15.4) 5 (27.8) 5 (33.3) 1 (12.5) 4 (57.1)
No 35 (79.6) 22 (84.6) 13 (72.2) 10 (66.7) 7 (87.5) 3 (42.9)
*P , 0.05 for STI clinic, male vs female.
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acquisition, once the peak viremia has subsided and after
more sensitive antibody tests can detect antibodies, but before
they are concordant positive for antibodies. Conversely,
persons with AHI from STI clinics appear to be presenting
earlier, possibly in response to STI-related symptoms associ-
ated with an infection acquired around the time of HIV
infection. Based on higher VLs and the presence of genital
sores/ulcers, persons with AHI tested at STI clinics may be
more likely than their acutely-infected counterparts tested at
HTC clinics to transmit HIV.
Risk behaviors at both clinic types, including infrequent
condom use and multiple sexual partners, reinforce the impor-
tance of screening for AHI to reduce forward transmission.
Although behaviors among the entire screened population at STI
and HTC clinics were similar, differences by AHI were
observed. In the STI clinics, all women with AHI reported only
1 partner within the last 3 months. One possible explanation for
this is that women were infected by their primary partner as
a consequence of a concomitant STI in the woman or her
partner. Alternatively, women may be more likely to under-
report multiple partners. The number of HIV-negative partners is
critical to appreciating the role of AHI in transmission events,
and detailed behavioral data from the pilot randomized
controlled trial, forming the basis of the current study, will help
elucidate true partnership patterns among these women.
Targeting AHI testing based on risk behaviors and
select acute retroviral symptoms may improve AHI screening
efficiency and could be a more cost-effective option for AHI
screening in high-prevalence, resource-limited settings. After
symptom-guided testing in Uganda, Mozambique, Kenya,
and South Africa, 1%–3% of adults in outpatient settings had
AHI.19–22 We evaluated performance of a previously validated
risk score that weighs symptoms, antibody results, and risk
behaviors to prioritize screening for persons at greatest risk of
AHI.26,33 Despite having been developed in the context of an
STI clinic, the algorithm performed better when applied to
HTC patients; we could identify .70% of all new infections
by screening only 12% of all HTC clients. This observed
efficiency may be driven by the higher frequency of
discordant rapid tests among HTC patients, a heavily-
weighted component of the risk score. Discordant antibody
results had a 24% positive-predictive value for AHI, similar to
that observed in previous studies of AHI in this population.26
One advantage of the risk score is that it goes beyond
symptoms, incorporating risk behaviors and biologic markers
(antibody test discordancy) that are often associated with
AHI. These elements are critical in light of the nontrivial
proportion of patients presenting with atypical symptoms of
AHI.34 However, the value of the risk score should be
evaluated in the context in which it was tested, namely high
prevalence settings in the background of endemic HIV. The
utility of targeted screening using symptoms of early infection
may not be realized in low-prevalence settings.35 Although
we did not capture costs associated with AHI screening in this
study, use of targeted screening may be suitable in HTC
clinics, containing costs by improving efficiency of AHI
screening in this population with a lower prevalence of AHI.
As the first report of AHI screening from HTC, there is
no comparator by which to evaluate change in AHI preva-
lence in this population. In STI clinics, despite a decline in
AHI prevalence, the proportion of all HIV diagnoses attribut-
able to AHI appears to be steady or higher compared with
previous studies. Historically, AHI rates among STI clinic
patients in Malawi ranged from 2% to 5% of HIV-seronegative
patients, accounting for 3%–5% of new HIV diagnoses.23,24 In
this study, among screened HIV-seronegative STI patients,
1.0% were acutely infected, accounting for 2.3% of new HIV
diagnoses. However, we were only able to screen one-third of
the seronegative patients. At the STI clinic, if we extrapolate
the observed rates of eligibility and AHI to the approxi-
mately 13,600 seronegative persons who were not screened
for the study, and the approximately 5500 who did not
consent, we anticipate 70 persons with AHI were missed
among all seronegative patients. Under these assumptions,
acute infection may account for up to 5.7% of new HIV
diagnoses at STI clinics.
AHI screening acceptability observed in this study is
likely a gross underestimate of true testing acceptability in
light of the testing occurring in the research setting. Although
two-thirds of all eligible patients accepted testing, we do not
have information regarding why eligible patients refused AHI
testing. Eligible patients at STI clinics were more likely to
accept AHI testing compared with their HTC counterparts.
This difference could reflect differential perceived risk of AHI
between these 2 patient populations. Alternatively, the
difference may be due to superior prestudy sensitization by
counselors at STI clinics, many of whom had previous
experience screening for AHI. In this study, accepting AHI
testing meant committing to the additional time necessary for
provision of consent and data collection. Consent and data
collection may have also been a barrier for eligibility
assessment; we observed a lower-than-desired rate of screen-
ing for study eligibility with just over half of all HIV-
seronegative patients evaluated. However, in that we did not
use symptom-based assessments before eligibility assess-
ment; the seronegative patients who were assessed for study
eligibility were not any more or less likely to have AHI.
Although critical elements in the context of our investigation,
consent and data collection barriers are unlikely to be
obstacles to AHI testing outside of a research setting. We
would expect higher rates of testing acceptability if such
screening was incorporated into routine algorithms.
Rapid specimen testing and patient notification of AHI
status is critical. Using pooled HIV RNA PCR, nearly 99% of
specimens were tested within 7 days of screening. The 21-day
protocol-permitted window may miss peak viremia, but is still
within the 10–12 week period of increased infectiousness and
represents a significant improvement over the current stan-
dard of care. Nonetheless, faster testing turnaround time may
reduce transmissions occurring between screening and result
availability. Unfortunately, no effective point-of-care AHI
tests are available.36–38 Fourth generation enzyme linked
immunoassays may be a suitable and cost-effective alterna-
tive to HIV RNA,39 but still require expensive and extensive
laboratory infrastructure. The serum volume required by these
assays precludes fingerstick collection, in contrast to RNA
testing which can pool small volumes of serum.40,41 Current
HIV testing algorithms in Malawi use exclusively fingerstick;
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counselors are rarely trained in venous phlebotomy. Despite
the complexity of HIV RNA PCR, standard centralized labs
serving numerous clinics within a city or region may facilitate
use of this technology, yielding greater daily screening
volume, and enabling larger pool sizes for more efficient
testing.41 HIV RNA will play a prominent role in AHI
screening until fourth generation assays can test with smaller
whole blood volume, or point-of-care devices demonstrate
their suitability for use in the field.
Even without point-of-care options, notification of AHI
results was efficient. Among the 46 patients who were
enrolled into the subsequent pilot study, the median time
from screening to enrollment was 7 days (data not shown),
indicating that most patients were tested and informed of their
AHI results within 7 days. The tracing efforts in this study
included a team of community educators who used patient-
provided information to locate acutely-infected persons.
Resource-utilization for these efforts was not captured.
Although generalizability to more rural areas merits further
evaluation, use of community educators may be scalable.
We have demonstrated that AHI testing can be
incorporated into routine HIV testing procedures and may
be an acceptable add-on to existing antibody-based testing
algorithms. AHI prevalence was significantly higher among
STI clinic patients compared with HTC clinic patients, and
accounts for a substantial proportion of all new HIV
diagnoses. We demonstrated that targeted screening for
HTC patients using a risk score is an efficient means of
identifying acute infection, and would help focus screening
resources in this lower prevalence population. Based on our
results, AHI screening in both STI and HTC clinic settings
may be warranted in high-incidence settings, such as Malawi,
and should be made a priority for HIV prevention. Additional
considerations, including cost-effectiveness and feasibility
outside of a controlled trial setting, will be critical to design
and implement sound AHI-focused testing policies. We
recommend targeted AHI screening for HTC patients and
universal AHI screening for STI patients.
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